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Abstract: A recent study (FIBROWALK) has supported the effectiveness of a multicomponent
treatment based on pain neuroscience education (PNE), exercise therapy (TE), cognitive behavioral
therapy (CBT), and mindfulness in patients with fibromyalgia. The aim of the present RCT was:
(a) to analyze the effectiveness of a 12-week multicomponent treatment (nature activity therapy for
fibromyalgia, NAT-FM) based on the same therapeutic components described above plus nature
exposure to maximize improvements in functional impairment (primary outcome), as well as pain,
fatigue, anxiety-depression, physical functioning, positive and negative affect, self-esteem, and
perceived stress (secondary outcomes), and kinesiophobia, pain catastrophizing thoughts, personal
perceived competence, and cognitive emotion regulation (process variables) compared with treatment
as usual (TAU); (b) to preliminarily assess the effects of the nature-based activities included (yoga,
Nordic walking, nature photography, and Shinrin Yoku); and (c) to examine whether the positive
effects of TAU + NAT-FM on primary and secondary outcomes at post-treatment were mediated
through baseline to six-week changes in process variables. A total of 169 FM patients were randomized
into two study arms: TAU + NAT-FM vs. TAU alone. Data were collected at baseline, at six-week of
treatment, at post-treatment, and throughout treatment by ecological momentary assessment (EMA).
Using an intention to treat (ITT) approach, linear mixed-effects models and mediational models
through path analyses were computed. Overall, TAU + NAT-FM was significantly more effective than
TAU at posttreatment for the primary and secondary outcomes evaluated, as well as for the process
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variables. Moderate-to-large effect sizes were achieved at six-weeks for functional impairment,
anxiety, kinesiophobia, perceived competence, and positive reappraisal. The number needed to treat
(NNT) was 3 (95%CI = 1.6–3.2). The nature activities yielded an improvement in affective valence,
arousal, dominance, fatigue, pain, stress, and self-efficacy. Kinesiophobia and perceived competence
were the mediators that could explain a significant part of the improvements obtained with TAU
+ NAT-FM treatment. TAU + NAT-FM is an effective co-adjuvant multicomponent treatment for
improving FM-related symptoms.
Keywords: fibromyalgia; multicomponent treatment; pain neuroscience education; exercise therapy;
cognitive behavioral therapy; mindfulness; nature exposure; randomized controlled trial
1. Introduction
Fibromyalgia (FM) is a syndrome that affects around 2% of the general population [1] and has a
strong impact on activities of daily living [2]. It usually affects women [3], but some recent studies
have reported a prevalence of up to 40% in men due to the use of the 2016 American College of
Rheumatology (ACR) diagnostic criteria [4,5]. High direct medical costs and indirect costs of this
condition represent a great burden for the healthcare system of developed countries [6].
The etiopathogenesis of FM remains poorly understood, but the sensitization of the central
nervous system (CNS) (i.e., central sensitization or CS) involving an imbalance between pain
descending inhibitory and facilitatory pathways [3] appears to be involved in both the development
and chronification of pain [7]. In the pathogenesis of central sensitization syndromes (SSC) such as
FM, the phenomenon of CS is considered to be more relevant than that of peripheral sensitization,
although it has been accepted that both can be involved [8]. CS is a broad concept involving a large
variety of complex pathophysiological mechanisms [9,10] that represents a challenge for researchers
and clinicians in the field of SSC.
The main clinical characteristics of FM include chronic widespread musculoskeletal pain, increased
pain sensitivity incorporating allodynia and hyperalgesia, but without a known structural pathology in
muscles, tendons, ligaments, or joints. It is usually accompanied by fatigue, sleep problems, paresthesia,
joint stiffness, headache, cognitive problems, depression, and/or anxiety disorders [4,11].
Given that FM is a complex multidimensional disease that involves a variety of predisposing
factors, a multicomponent approach is usually recommended, combining pharmacological and
non-pharmacological treatments [12–15]. Empirical evidence supports the use of multicomponent
treatments as the most beneficial interventions for FM patients and it has been claimed that they should
be considered as the gold standard [16–18]. Regarding pharmacological treatment, the European
League against Rheumatism (EULAR) recommendation for FM patients is to only use medication to
control pain and sleep disturbances [19].
Use of the following therapeutic components have received empirical support and are considered
to be optimal elements in multicomponent interventional packages: pain neuroscience education (PNE),
exercise therapy (ET), cognitive behavioral therapy (CBT), and mindfulness training (MT) [20–27]. A
recent randomized controlled trial (RCT) [27], which integrated, for the first time, the aforementioned
four therapeutic approaches, PNE, ET, CBT and MT, found moderate to large effect sizes in the
improvement of the core FM symptoms.
At the same time, therapeutic programs based on activities in nature have shown promise for
improving mental health [28–31] in various clinical populations [32,33]. A growing number of studies
suggest that exposure to nature directly produces effects in the affective (positive and negative emotions,
and stress) and cognitive (attention, memory, etc.) domains, as well as can upward modulate the
beneficial effects of physical activity. Likewise, it has been proposed that practice in a natural context
could increase adherence to therapies based on the practice of physical activity (which has been called
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“green exercise”). These effects have been also tested in chronic pain patients [34] and those with
FM [35]. However, to our knowledge, the synergistic effects of the therapeutic components mentioned
above, and nature-based activities have not yet been tested in patients with FM.
Taking this gap in the literature as our starting point, the NAT-FM (acronym for nature activity
therapy for FM) study aims to empirically test, for the first time, the impact of combining all the
approaches described above, that is, integrating PNE, TE, CBT, MT, and exposure to natural contexts.
NAT-FM is rooted on the body of scientific evidence reported in various studies [27,36], assumes a
process-based therapy approach [37] and is expected to constitute an add-on therapy conceived as a
new generation of therapeutic programs for FM, chronic pain in general, and various health problems,
by combining different approaches in natural contexts.
The objective of this RCT was three-fold: (a) to analyze the effectiveness of a 12-week
multicomponent treatment based on PNE, TE, CBT, MT, and nature exposure, as an add-on to
treatment as usual (TAU) to improve functional impairment (primary outcome), as well as pain, fatigue,
anxiety-depression, physical functioning, positive and negative affect, self-esteem, and perceived stress
(secondary outcomes), kinesiophobia, pain catastrophizing thoughts, personal perceived competence,
and cognitive emotion regulation (process variables) compared with TAU; (b) to preliminarily assess
the specific effects of the nature activities included in TAU + NAT-FM; and (c) to examine whether
the positive effects of TAU + NAT-FM on primary and secondary outcomes (post-treatment) were
mediated through baseline to six-week changes in process variables.
2. Materials and Methods
2.1. Design
A detailed description of the study protocol is provided elsewhere [28]. A 12-week RCT was
conducted in which the study participants were randomly allocated to 2 arms (using computer
generated numbers): (a) TAU (control group) and (b) TAU + NAT-FM (active group). Data collection
was conducted at baseline (pre), after week six of treatment (during), and after (post) treatment
completion. Clinical assessments were conducted at pre-established time points: (a) classical structural
assessment (CSA): pre, during and post-treatment; and (b) EMA: intrasession (nature activity log).
Therefore, this study combines different types of assessments (CSA + EMA) to obtain more precise
information about the temporal dynamics of the variables to be evaluated and, specifically, to record
the affective and cognitive impact of each nature activity. Before the RCT, a proof of concept [38] of a
simplified version of the study protocol was performed in order to assess its feasibility.
This study was conducted in accordance with the ethical standards set forth in the 1964 Declaration
of Helsinki and its subsequent amendments. The hospital’s Ethics Committee of the University Hospital
Vall d’Hebron (UHVH) evaluated and approved the study protocol (PR(AG)120/2018). This RCT was
registered at ClinicalTrials.gov (NCT04190771) and we have followed the guidelines issued by the
Consolidated Standards of Reporting Trials (CONSORT) [39].
2.2. Participants
A total of 169 out of 280 patients with FM who met the selection criteria were recruited by a
physical therapist (M.S.) of the Central Sensitivity Syndromes Specialized Unit (CSSSU) at the UHVH
from September to November 2019 and the patients participated in the TAU + NAT-FM study between
November 2019 and February 2020. As shown in Figure 1, these patients were randomly allocated into
two study arms, active group (n = 84), and a control group that received only TAU (n = 85). The active
study arm included four waves of group-based therapy (approximately n = 21 per group), that is, all the
groups did not receive the interventions and evaluations in the same period due to logistical reasons.
The inclusion criteria were: (a) being adults ≥ 18 years old, (b) meeting the 2010/2011 ACR
diagnostic criteria for FM [4,40–42], and (c) agreeing to voluntarily participate in the study. Participants
were excluded if: (a) they were already participants in concurrent or past (last year) RCTs and (b)
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they reported comorbidity with severe mental disorders or neurodegenerative diseases that would
limit their capacity to participate in the study. Patients having a severe mental or neurodegenerative
disorder that could make it difficult to follow up any type of group clinical session or physical activity,
were not included in the list of candidates to be recruited. Once the list was defined according to this
exclusion criterion, a second filtering was carried out excluding patients with a diagnosis of mental
health disorder, who may have difficulties in participating in clinical sessions in a natural/outdoor
context. This essentially includes patients diagnosed with agoraphobia. In this RCT, no participant
was excluded due to this criterion. The CONSORT 2010 flow chart is shown in Figure 1.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 4 of 23 
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Figure 1. Flowchart of the nature activity therapy for fibromyalgia (NAT-FM) study following the
Consolidated Standards of Reporting Trials (CONSORT) statement. ITT, intention-to-treat; n = 0
indicates that none of the participants attended the specified number of sessions.
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2.3. Procedure
The procedure for recruiting the participants can be found in the study protocol [28]. In brief,
all patients were consecutively screened by the physical therapist (M.S.) in the Central Sensitivity
Syndromes Specialized Unit (CSSSU) at the UHVH in the context of clinical practice. Those participants
who met the inclusion/exclusion criteria were scheduled for a face-to face interview with the principal
researcher (M.S.) to provide an overview of the study. Those participants who were interested and
agreed to participate signed a written informed consent. Each participant was then assigned to an
alphanumeric code list using the Statistical Package for Social Sciences (IBM-SPSS v26, (Armonk, NY,
USA) for random allocation to either TAU + NAT-FM or TAU.
2.4. Study Arms
2.4.1. TAU + NAT-FM
The active group received PNE, TE, CBT, MT, and nature exposure. All the sessions were
conducted outdoors. The TAU + NAT-FM protocol integrates the FIBROWALK protocol [27], replacing
the exercise therapy described there for activities carried out in nature such as Yoga, Nordic walking,
photography, and Shinrin Yoku. Tables 1 and 2 provide an updated outline of the TAU + NAT-FM
program described elsewhere [27,28].
Table 1. Outline of active group sessions in NAT-FM treatment.
Review Phase (15 min)
• Comment on the duties of the previous session.
• Review of contents of the previous session.
Main Phase (1 h 40 min)
• 20 min Pain Neuroscience Education (PNE).
• 40 min Exercise therapy (TE) or Nature Activity (NA) or both (20 min each).
• 20 min Cognitive Behavioral Therapy (CBT).
• 20 min Mindfulness training (MT)
Sessions:
1. PNE (1,2) + CBT (1) + MT (1)
2. PNE (3,4) + TE (2) + CBT (2, 13–18) + MT (2)
3. PNE (5,6) + TE (2) + CBT (3, 19–23) + MT (3) + NA (3)
4. PNE (7,8) + TE (4) + CBT (4, 24–28) + MT (4)
5. PNE (9,10) + TE (4) + CBT (5, 15–28) + MT (5) + NA (3)
6. PNE (11) + TE (2) + CBT (6, 29–34) + MT (6) + TE (4)
7. PNE (12) + TE (4) + CBT (7,8, 35–40) + MT (7,8) + NA (5)
8. PNE (13) + TE (4) + CBT (9, 41–44) + MT (9) + NA (3)
9. PNE (14) + TE (2) + CBT (10, 45–48) + MT (10)
10. Family Session (PNE 1–16) + NA (3)
11. PNE (15) + TE (4) + CBT (11, 47–48) + MT (11) + NA (5)
12. PNE (16) + TE (4) + CBT (12, 18, 28, 34, 40, 48) + MT (12)
Homework (5 min)
• TE (1): first month once per week, second month twice per week, and third month three times per week.
• Cognitive (related to CBT and MT) and physical tasks to do at home to increase the patient’s resistance
involving a constant challenge for them.
Note: The numbers in parentheses from 1 to 16 of pain neuroscience education (PNE), from 1 to 48 of CBT, from 1 to 5
of TE/NA and from 1 to 12 of mindfulness training (MT) are explained on Table 2. The exercise therapy was designed
following the recommendations of the American College of Sports Medicine (ACSM) and was performed following
the same procedures described elsewhere (Serrat 2020). TE/NA, therapeutic exercise with nature exposition.
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The TAU + NAT-FM sessions were carried out once per week (2 h) for 12 consecutive weeks
and were run in four groups arranged in a series. The sessions were directed by M.S., who is the
physiotherapist of the CSSU of Vall d’Hebron University Hospital, and also a psychologist and sports
technician with the required legal qualifications and extensive training for conducting the correct
execution of this treatment. M.S. also had the help of a FM patient who had previously successfully
completed the FIBROWALK program and joined the groups to explain her experience and to motivate
them to maintain adherence to the therapy.
Patients of this intervention arm were requested for maintaining the prescribed drugs adjusted to
their own symptomatic profile, and therefore to not change their medication regimen throughout the
three-month period.
Table 2. Steps of the multicomponent treatment: PNE, exercise therapy, cognitive behavioral therapy
(CBT), mindfulness and nature exposure.
Pain Neuroscience Education (PNE)
1. Disassembling beliefs.
2. Danger signals: modulation and modification.
3. Concept of pain, fatigue, and pain system.
4. Concept of central nervous system and central sensitization. The role of the brain.
5. Acute vs. Chronic Pain: The purpose of acute pain and how it originates in the nervous central
system (CNS).
6. Pain vs. damage.
7. Pain neuromatrix theory and representation of the virtual body.
8. Nociception, nociceptors, action potential, peripheral sensitization, and synapses.
9. Ascending and descending inhibitory pathways, spinal cord.
10. Relationship with attention, perception, pain cognitions, and pain behaviors.
11. Allodynia and hyperalgesia, hypersensitivity of nervous central system.
12. Pain memory, pain perception, and autoimmune evaluation error.
13. Relationship with stress. Etiology.
14. Neuroplasticity and how the pain becomes chronic.
15. Relationship with emotions.
16. Re-education, gradual activity, and exercise therapy.
Exercise Therapy (TE)/Nature Activities (NA) Used to Work the Cognitive Targets
1. TE: Hiking *
2. TE: Yoga **
3. NA: Photography
4. TE: Nordic Walking **
5. NA: Shinrin Yoku ***
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Table 2. Cont.
Cognitive Behavioral Therapy (CBT)
General Issues:
1. Relaxation and breathing.
2. Modulating factors of pain.
3. Catastrophizing and fear of movement.
4. Painful experiences: confrontation.
5. Vital values and setting goals.
6. Organization of time.
7. Sleep patterns.
8. Sexual issues.
9. Handling of attention.
10. Cognitive restructuring.
11. Emotional regulation and assertiveness.
12. Troubleshooting.
Cognitive Targets:
Positive affect
13. Understand the concept of positive emotions.
14. Recognize the relationship between positive emotions, pain, and fatigue.
15. Recognize the importance of actively searching for sources of positive emotions.
16. Identify sources of positive emotions in the context of the sessions.
17. Learn to pay attention to stimuli/conditions that generate positive emotions.
18. Transfer: How to work positive affect in day life.
Self-efficacy
19. Understand the concept of self-efficacy.
20. Recognize the relationship between self-efficacy, pain, and fatigue.
21. Recognize the importance of adapting self-efficacy to real capacity.
22. Become aware of the process of self-efficacy elaboration.
23. Recognize the dynamics of self-efficacy.
24. Identify the sources of self-efficacy.
25. Identify the biases in the creation of self-efficacy.
26. Learn how to stop and replace the biases in the creation of self-efficacy.
27. Relationship between self-efficacy and self-esteem.
28. Transfer: How to work self-efficacy in day life.
Negative affect
29. Understand the concept of negative emotions.
30. Recognize the relationship between negative emotions, pain, and fatigue.
31. Recognize the adaptive function of negative emotions
32. Assess the importance of emotional regulation to reduce negative emotions
33. Learn to pay attention to the stimuli/conditions that generate negative emotions
34. Transfer: How to reduce negative affect to everyday life.
Catastrophic thinking
35. Understand the concept of catastrophism.
36. Recognize the relationship between catastrophism, pain, and fatigue.
37. Learn to recognize the catastrophic thoughts.
38. Learn to pay attention to the catastrophic thoughts
39. Learn to stop and replace the catastrophic thoughts.
40. Transfer: How to work catastrophism on an everyday basis.
Emotional regulation
41. Understand the concept of emotional regulation.
42. Recognize the relationship between emotional regulation, pain, and fatigue.
43. Identify the 9 types of cognitive regulation of emotions.
44. Identify the relationship between emotional regulation, pain, and fatigue.
45. Learn to pay attention to emotional regulation.
46. Learn to identify the type of emotional regulation usually employed in day life.
47. Learn to stop and subtract inappropriate emotional regulation for a proper one.
48. Transfer: How to work emotional regulation in everyday life.
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Table 2. Cont.
Mindfulness Training (MT)
1. An Introduction to Body Scanning.
2. Elementary Awareness.
3. Sitting Practice and introduction to Yoga.
4. Mindfulness and the Brain.
5. Mindfulness and communication: guilt, empathy, and conflict management.
6. Responding vs. reacting.
7. Dig deeper into personal practice.
8. Mindfulness and Compassion: Strength vs. Cooperation.
9. Stress Management.
10. Thoughts Management.
11. Management of difficult emotions or feelings.
12. Dig deeper into personal practice.
Note: * Hiking is a homework assignment to do as an exercise therapy with cognitive targets; ** hiking, yoga and
Nordic walking has been done as an exercise therapy following the same procedures described elsewhere [27];
*** Shinrin Yoku is understood as mindfulness in a natural context.
2.4.2. TAU
In the present study usual care was based on basic education of the disease, advice on aerobic
exercise and pharmacological treatment adjusted to the personal picture of each patient that basically
consisted of duloxetine (30–60 mg/day) or amitriptyline (25 mg/day), pregabaline (150–300 mg/day) or
tramadol at low doses, in monotherapy or combination... In the present study, we asked the patients
to not change their medication regimen throughout the three-month period. For ethical reasons, we
provided some complementary unstructured advice on PNE and aerobic exercise adapted to the
physical capacities of the patients at the beginning of the study. Therefore, this might be regarded
as slightly “enriched” usual care. Patients in the control group were placed on a waiting list to be
recruited for the next TAU + NAT-FM treatment at the end of the present RCT (three months).
2.5. Outcome Measures
2.5.1. Classical Structural Assessment (CSA) at Specific Time Points
Primary Outcome
The fibromyalgia impact questionnaire revised (FIQR) [43] was used to measure functional
impairment during the last week. This instrument consists of three dimensions: physical dysfunction
(scores from 0 to 30), overall impact (scores from 0 to 20), and intensity of the symptoms (scores from
0 to 50). Higher scores indicate greater impairment. The Spanish version shows adequate internal
consistency (Cronbach’s α = 0.93) [44–46].
Secondary Outcomes
The visual analog scale (VAS) [43] was used to measure fatigue and pain, with scores ranging from
0 to 10. Higher scores are taken to indicate greater impairments due to fatigue and pain, respectively.
The hospital anxiety and depression scale (HADS) [47] was used to quantify the severity of anxiety
and depression symptoms. It consists of two dimensions (anxiety and depression) of 7 items each, with
a four-point Likert scale. Total scores of each scale, HADS-A and HADS-D, range from 0 to 21. Higher
scores indicate greater symptom severity. The Spanish version shows adequate internal consistency
for HADS-A (Cronbach’s α = 0.83) and for HADS-D (α = 0.87) [48].
The physical functioning component of the 36-item short form survey (SF-36) [49] was used to
assess physical function. This dimension comprises a total of 10 items, with a three-point Likert scale.
Total scores are transformed in order to range from 0 to 100. Higher scores indicate better physical
functioning. The Spanish version shows adequate internal consistency (Cronbach’s α = 0.94) [50].
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The positive affect and negative affect schedule (PANAS) [51] was used to evaluate affect. It has
two dimensions (positive affect and negative affect) of 10 items each, answered on a 5-point Likert
scale. Higher scores indicate a greater presence of specific affectivity. The Spanish version presents
adequate internal consistency for PANAS-PA (Cronbach’s α = 0.92) and for PANAS-NA (Cronbach’s
α = 0.88) [52].
The Rosenberg self-esteem scale (RSES) [53] was used to measure self-esteem. This instrument
consists of 10 items that are answered on a four-point Likert scale. The total scores of each scale range
from 10 to 40. Higher scores indicate higher self-esteem. The Spanish version has adequate internal
consistency (Cronbach’s α = 0.87) and acceptable test-retest reliability (r = 0.72 to 0.74) [54].
The perceived stress scale (PSS-4) [55] was used to evaluate the perceived stress during the last
month. In this study the short four-item version was employed, which is answered on a five-point
Likert scale; therefore, total scores can vary from 0 to 16. Higher scores indicate higher perceived stress.
The Spanish version shows acceptable internal consistency (Cronbach’s α = 0.77) [56].
Process Variables
The Tampa scale for kinesiophobia (TSK) [57] was used to measure fear of pain and movement.
This scale consists of 11 items, which are answered on a four-point Likert scale. Total scores of each
scale range from 11 to 44. Higher scores are taken to indicate greater fear of pain and movement. The
Spanish version has adequate internal consistency (Cronbach’s α = 0.79) [58].
The pain catastrophizing scale (PCS) [59] was used to evaluate pain catastrophizing thoughts. This
scale consists of three dimensions (rumination, magnification, and helplessness), with 13 items that are
answered on a five-point Likert scale, and total scores ranging from 0 to 52. Higher scores indicate
greater catastrophic thinking. The Spanish version shows adequate internal consistency (Cronbach’s
α = 0.79) and acceptable test-retest reliability (r = 0.84) [60].
The personal perceived competence scale (PPCS) [61] was used to measure perceived competence.
This scale consists of 8 items that are answered on a six-point Likert scale. Total scores of each scale
range from 8 to 48. Higher scores indicate greater perceived competence. The Spanish version shows
adequate internal consistency (Cronbach’s α = 0.83) [62].
The cognitive emotion regulation questionnaire (CERQ) [63] was used to assess individual
differences in the cognitive regulation of emotions. This study used the short 18-item version.
Responses were given on a five-point Likert scale (from 1 = almost never to 5 = almost always). Higher
scores indicate higher frequency of use of each cognitive strategy. The Spanish version shows adequate
internal consistency (Cronbach’s αs ranging from 0.77 to 0.93) and acceptable test-retest reliability
(r ranging from 0.60 to 0.85) [64].
2.5.2. Ecological Momentary Assessment (EMA)
The ecological momentary assessment (EMA) is a longitudinal, prospective research methodology
that evaluates daily the variables of interest in real time and in a real context [65]. This methodology
shows high reliability and validity [66], and in clinical research it is of special interest for the continuous
assessment of the processes moderating the effectiveness of the interventions. It is also employed to
evaluate the dynamics of the transfer and generalization of the effect of therapeutic sessions to the
daily life of patients [67]. Its use as a complementary evaluation of psychological processes in clinical
studies has recently increased thanks to the universalization of smartphones and apps. EMA was used
to explore the effect of the different activities included in the TAU + NAT-FM treatment, assessing the
specific short-term impact of each activity in terms of transferring the treatment effects to daily life.
The intra-session assessments were conducted before and after each of the treatment sessions.
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2.6. Statistical Analysis
In order to detect potential differences in sociodemographic and baseline clinical characteristics,
we applied the χ2 test with continuity correction (or the two-sided Fisher exact test when appropriate)
for categorical data and the student-Fisher t-test for continuous variables.
The main between-group analysis to assess the treatment effect was conducted on an
intention-to-treat (ITT) basis, assuming data were missing at random. Linear mixed models were
applied with maximum likelihood regression to account for the correlation between repeated measures
for each individual. Multiple imputation has been reported to be unnecessary when computing linear
mixed models [65]. Regression coefficients were calculated along with the respective 95% confidence
intervals (95% CIs) for each group × time interaction. Effect sizes were reported using Cohen’s d
for each pair comparison, using the pooled baseline SD to weight the differences in the pre-post
mean values and to correct for the population estimate [66]. Separate models were estimated for each
secondary outcome using the same strategy. The Benjamini–Hochberg correction test was applied
to detect false discovery when performing multiple comparisons, since this test has been reported to
overcome some limitations of other similar tests [66].
To further assess the clinical significance of improvements in the primary outcome (i.e., FIQR), we
classified the sample into two categories: responders vs. non-responders to treatment. A responder
is a patient that had decreased their FIQR posttreatment score by at least 20% in comparison with
their baseline assessment [43]. This classification was later used to compute the number needed
to treat (NNT), which refers to the estimated number of patients that should be treated with the
new proposed intervention (i.e., TAU + NAT-FM) compared with the control group for obtaining 1
additional responder. The NNT was calculated along with a 95% CI.
To preliminarily assess the effect of the various activities included in TAU + NAT-FM (i.e., yoga,
Nordic walking, nature photography, and Shinrin Yoku), paired-sample student-Fisher’s t-tests were
conducted for each activity, analyzing the change produced in affective valence, arousal, dominance,
fatigue, pain, stress and self-efficacy after practicing the activity.
Finally, we also examined whether the effects of TAU + NAT-FM on primary and secondary
outcomes (post-treatment) were mediated through baseline to six-week changes in process variables
(i.e., TSK, PCS, PPCS, and CERQ). We computed bivariate Pearson correlations between the baseline to
six-week change in the process variables and the pretreatment to posttreatment change in the outcomes
in order to detect potential significant relationships. In those cases in which more than two changes
in process variables presented significant correlations with changes in clinical outcomes, only the
two highest correlations were selected to ensure sufficient statistical power. We explored the direct
and indirect associations between the treatment condition (TAU + NAT-FM vs. TAU as independent
variable), TSK, PCS, PPCS, and CERQ subscales (mediators), and primary and secondary outcomes
(dependent variables) using path analyses. Only data from participants with no missing data were
used for this analysis (sample of completers). Regression coefficients (B) of bias-corrected bootstrapped
indirect effects were calculated, as well as the corresponding SEs and 95% CIs [68].
Data analyses were computed using IBM-SPSS v26 and MPlus v7 (https://www.statmodel.com/).
A 5% significance level was adopted in all two-tailed tests.
3. Results
3.1. Baseline Sociodemographic and Clinical Characteristics of the Groups
As can be seen in Table 3, no significant between-group differences were found in terms of
sociodemographic variables (all p ≥ 0.08). The patients were female (99%), middle-aged (mean ± SD,
54 ± 9), and slightly overweight (body mass index, BMI: mean ± SD, 27 ± 6) and they were able to recall
being ill for approximately 18 years. Most patients 59% were married or living with a partner, 63%
lived accompanied, 50% had completed secondary studies, 50% were in paid employment, and 50%
were processing some kind of disability certification at baseline. In relation to comorbidity, 85% had
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chronic fatigue, 32% multiple chemical sensitivity, 46% irritable bowel syndrome, and 58% migraines.
Finally, 40% of the participants were taking more than two medications.
Table 3. Demographic characteristics of treatment as usual (TAU) + NAT-FM and TAU participants.
TAU + NAT-FM (n = 84) TAU (n = 85) t/χ2 p
General measures
Gender, n of women (%) 82 (97.60) 85 (100) 0.74 0.39
Age, M (SD) 54.12 (8.62) 53.15 (9.06) 0.32 0.57
BMI (kg/m2), M (SD) 27.65 (5.49) 26.75 (5.75) 0.48 0.62
Years of illness, M (SD) 19.61 (11.99) 16.75 (9.74) 2.92 0.08
Married or in couple, n (%) 57 (67.8) 43 (50.6) 10.41 0.34
Cohabitating, n (%) 38 (44.2) 69 (81.2) 1.84 0.39
Secondary studies, n (%) 38 (45.3) 46 (54.7) 7.45 0.15
Labor assets, n (%) 43 (52.0) 40 (48.0) 18.52 0.09
Accreditation of disability in process, n (%) 30 (36.0) 54 (64.0) 1.13 0.29
Comorbidity with CSS, f (%)
Chronic fatigue 71 (84.6) 72 (85.3) 0.32 0.59
Multiple chemical sensitivity 30 (35.8) 25 (29) 1.72 0.17
Irritable bowel syndrome 38 (45.9) 39 (46.3) 0.08 0.70
Migraines 50 (59) 49 (57.8) 0.07 0.92
Medication, f (%)
Mix of more than two medications 27 (32.9) 41 (47.7) 4.71 0.41
Note: The values represent means (M) and standard deviation (SD) or frequency (n) and percentages (%), in their
respective order of presentation. BMI = body mass index. Significant values (p < 0.05) should be shown in bold.
There are no statistically significant group differences. CSS, central sensitization syndromes.
In the control intervention group (TAU + NAT-FM), there were 10 dropouts (11.7%), whilst in
the control group (TAU) there were none. Therefore, only 5.9% of the total sample withdrawn from
the study. When comparing baseline differences between dropouts and non-dropouts in terms of
sociodemographic and clinical variables, non-statistical differences were found.
3.2. Effects on Functional Impairment (Primary Outcome)
Descriptive statistics and between-group analyses for the FIQR data as the primary outcome of
this study are displayed in Table 4. In comparison with TAU, patients assigned to TAU + NAT-FM
achieved a significantly greater reduction in functional impact, showing considerable effects after six
weeks of treatment (d = 1.13) and at posttreatment (d = 1.83). These effects remained statistically
significant after the Benjamini–Hochberg correction test was applied.
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Table 4. Descriptive statistics and between-group analyses for primary and secondary outcomes
(intention to treat (ITT) approach).
TAU M (SD)
TAU +
NAT-FM M
(SD)
TAU vs. NAT-FM
d t (p) B (95% CI)
Primary outcome
FIQR (0–100) *
Baseline 73.21 (14.72) 73.07 (13.79)
6 weeks 69.68 (13.36) 58.78 (18.70) 1.13 −5.29 (<0.001) −10.96 (−15.04 to −6.88)
Post−treatment 69.18 (17.88) 50.69 (18.05) 1.83 −8.16 (<0.001) −18.07 (−22.43 to −13.72)
Secondary outcomes
VAS PAIN (0–10) *
Baseline 7.80 (1.61) 7.74 (1.52)
6 weeks 7.52 (1.59) 6.78 (1.99) 0.66 −3.02 (0.003) −0.77 (−1.28 to −0.27)
Post-treatment 7.47 (1.79) 5.60 (1.98) 5.62 −6.53 (<0.001) −1.79 (−2.33 to −1.25)
VAS FATIGUE (0–10) *
Baseline 7.76 (1.91) 7.61 (1.89)
6 weeks 7.32 (2.09) 5.98 (2.10) 0.77 −3.10 (0.002) −1.26 (−2.06 to −0.46)
Post-treatment 7.08 (2.34) 5.58 (2.00) 0.93 −3.87 (<0.001) −1.53 (−2.31 to −0.75)
HADS-A (0–21) *
Baseline 13.13 (4.22) 13.95 (3.80)
6 weeks 12.35 (4.07) 11.03 (4.25) 0.99 −4.52 (<0.001) −2.20 (−3.16 to −1.24)
Post-treatment 12.68 (4.63) 10.16 (4.19) 1.59 −7.08 (<0.001) −3.51 (−4.48 to −2.53)
HADS-D (0–21) *
Baseline 11.49 (4.64) 11.27 (3.71)
6 weeks 11.22 (5.02) 9.66 (4.47) 0.49 −2.23 (0.027) −1.10 (−2.07 to −0.13)
Post-treatment 11.67 (5.18) 8.18 (4.42) 1.45 −6.40 (<0.001) −3.37 (−4.41 to −2.34)
SF-36 (0–100) *
Baseline 26.04 (18.11) 27.03 (18.85)
6 weeks 28.24 (17.38) 35.09 (20.47) 0.53 2.41 (0.017) 5.51 (1.00 to 10.02)
Post-treatment 25.07 (15.86) 43.42 (20.92) 1.59 7.01 (<0.001) 17.15 (12.34 to 21.96)
PANAS-PA (0–50) *
Baseline 12.26 (4.38) 11.95 (5.79)
6 weeks 12.20 (4.30) 12.81 (5.39) 0.19 1.00 (0.319) 0.79 (−0.77 to 2.35)
Post-treatment 13.01 (4.03) 14.11 (4.28) 0.40 2.07 (0.039) 1.68 (0.08 to 3.27)
PANAS-NA (0–50) *
Baseline 14.34 (5.81) 13.84 (6.08)
6 weeks 13.94 (5.13) 13.22 (4.83) 0.13 −0.37 (0.714) −0.29 (−1.87 to 1.28)
Post-treatment 14.95 (4.50) 13.12 (4.24) 0.28 −1.38 (0.167) −1.14 (−2.75 to 0.48)
RSES (10–40) *
Baseline 15.41 (3.57) 16.03 (3.36)
6 weeks 15.48 (2.57) 16.60 (2.70) 0.37 1.23 (0.219) 0.68 (−0.40 to 1.75)
Post-treatment 16.25 (3.45) 16.53 (2.25) 0.03 −0.24 (0.809) −0.13 (−1.20 to 0.94)
PSS (0–16) *
Baseline 8.88 (2.15) 8.93 (2.31)
6 weeks 8.81 (1.90) 7.91 (1.87) 0.43 −1.88 (0.062) −0.77 (−1.57 to 0.04)
Post-treatment 8.88 (2.20) 8 (1.87) 0.37 −1.66 (0.098) −0.67 (−1.47 to 0.12)
Note: Mean and SD are not adjusted. When the Benjamini–Hochberg correction was applied to correct for multiple
comparisons, the following effects were not statistically significant: positive affect and negative affect schedule
(PANAS) positive (p = 0.059). The number of participants varied across assessment periods due to dropouts (see
flow chart). Significant values (p < 0.05) are shown in bold. * The baseline level of the variable is a significant
covariate in the model. B, regression coefficients; CI, confidence interval; d, Cohen’s d as an effect size measure; ITT,
intention-to-treat; NAT-FM; TAU, treatment-as-usual.
3.3. Effects on Pain, Fatigue, Anxiety-Depression, Physical Functioning, Positive and Negative Affect,
Self-Esteem, and Perceived Stress (Secondary Outcomes)
Patients that received TAU + NAT-FM showed a significant reduction in self-reported pain
compared with TAU. Moderate effects were found at 6 weeks (d = 0.66) and large effects at posttreatment
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(d = 5.62). Similar patterns were observed in depressive symptomatology after 6 weeks of treatment
(d = 0.49) and at posttreatment (d = 1.45) and in physical functioning at 6 weeks (d = 0.53) and at
posttreatment (d = 1.45). For the other secondary outcomes, a large effect of TAU + NAT-FM was
found in comparison with TAU for fatigue at 6 weeks (d = 0.77) and at posttreatment (d = 0.93)
and for anxiety at 6 weeks (d = 0.99) and at posttreatment (d = 1.59). The effects of all of these
secondary outcomes remained statistically significant after the Benjamini–Hochberg correction test
was applied. We found a small significant effect of TAU + NAT-FM compared with TAU for positive
affect at posttreatment (d = 0.40). This effect became marginally significant after computing the
Benjamini–Hochberg correction test. There were no statistically significant differences for the other
variables or measurement times.
3.4. Effects on Kinesiophobia, Pain Catastrophizing, Personal Perceived Competence, and Cognitive Emotion
Regulation (Process Variables)
Descriptive statistics and between-group analyses for the process variables are displayed in
Table 5. TAU + NAT-FM achieved a significantly greater reduction than TAU for kinesiophobia,
with large effects at both 6 weeks of treatment (d = 1.18) and at posttreatment (d = 2.20). The same
patterns were observed in pain catastrophizing at 6 weeks (d = 1.21) and at posttreatment (d = 2.03),
in personal perceived competence at 6 weeks (d = 0.72) and posttreatment (d = 1.20) and in positive
reappraisal (CERQ) at 6 weeks (d = 0.72) and posttreatment (d = 1.42). Moderate effects of TAU +
NAT-FM compared with TAU were found after 6 weeks of treatment for refocusing (CERQ) (d = 0.52)
and planning (CERQ) (d = 0.58), finding large effects at posttreatment for the same outcomes, i.e.,
refocusing (CERQ) (d = 0.99) and planning (CERQ) (d = 0.83). For the other process variables, a small
effect of TAU + NAT-FM was observed in comparison with NAT for acceptance (CERQ) at 6 weeks
(d = 0.47) and moderate effects were found at posttreatment for both acceptance (CERQ) (d = 0.53)
and perspective taking (CERQ) (d = 0.71). The effects of all of these secondary outcomes remained
statistically significant after the Benjamini-Hochberg correction test was applied. A small effect of TAU
+ NAT-FM in comparison with TAU was found in catastrophizing (CERQ) at 6 weeks (d = 0.47) and at
posttreatment (d = 0.85), although these latter effects became only marginally significant after applying
the Benjamini–Hochberg correction test.
3.5. Number Needed to Treat
Thirty-eight patients in the TAU + NAT-FM group (66.7%) reached the status of responder (i.e.,
showed a decrease in their FIQR total score by at least 20% in comparison with baseline assessment),
whilst only 15 patients in the TAU condition (20%) achieved this status. One patient (1.3%) from the
active group showed a reduction of more than 70% in the FIQR scale and a total of 6 patients (8.1%)
from this group showed a reduction of more than 60%.
The absolute risk reduction (ARR) in TAU + NAT-FM in comparison with TAU was 46.7%
(95% CI = 31.4 to 61.9), with NNT = 3 (95% CI = 1.6–3.2), meaning that 3 patients would need to be
treated with TAU + NAT-FM for one of them to become a responder, which would otherwise have not
been possible in the TAU group.
The responder group showed significantly higher scores with a small effect size (Cohen’s d ≤ 0.49)
in BMI (non-responders: 26.22 ± 5.91; responders: 28.25 ± 5.31), age (non-responders: 51.11 ± 9.31;
responders: 55.87 ± 6.81), years of illness (non-responders: 16.30 ± 8.98; responders: 21.66 ± 12.49),
and in perspective taking (CERQ) (non-responders: 4.91 ± 2.05; responders: 5.94 ± 2.34). The
non-responder group reported significantly higher scores with a small effect size (Cohen’s d ≤ 0.43)
in anxiety (non-responders: 14.16 ± 3.88; responders: 12.45 ± 4.06), depression (non-responders:
12.38± 4.21; responders: 10.66± 4.36), and pain catastrophizing thoughts (non-responders: 30.54± 11.34;
responders: 25.50 ± 12.66). There were no significant differences between groups in terms of any other
sociodemographic or clinical variables.
J. Clin. Med. 2020, 9, 3348 14 of 24
Table 5. Descriptive statistics and between-group analyses for process variables (ITT approach).
TAU M (SD) TAU+NAT-FM
M (SD)
TAU vs. TAU+NAT-FM
d t (p) B (95% CI)
TSK (11–44) *
Baseline 29.92 (7.58) 29.23 (7.40)
6 weeks 25.59 (6.46) 21.36 (6.83) 1.18 −5.35 (<0.001) −4.73 (−6.47 to −2.98)
Post-treatment 28 (7.44) 17.95 (4.97) 2.2 −9.65 (<0.001) −9.15 (−11.01 to −7.28)
PCS (0–52) *
Baseline 27.72 (12.65) 27.04 (11.33)
6 weeks 26.72 (13.25) 17.83 (9.56) 1.21 −5.53 (<0.001) −7.30 (−9.90 to −4.70)
Post-treatment 27.49 (13.35) 13.53 (8.87) 2.03 −8.93 (<0.001) −12.56 (−15.33 to −9.80)
PPCS
Baseline 25.05 (7.84) 23.77 (7.98)
6 weeks 25.35 (8.22) 27.50 (8.08) 0.72 3.44 (0.001) 3.73 (1.59 to 5.86)
Post-treatment 24.57 (8.50) 28.67 (8.62) 1.2 5.47 (<0.001) 6.17 (3.95 to 8.38)
CERQ Acceptance (0–20) *
Baseline 6.46 (2.33) 6.19 (2.27)
6 weeks 6.28 (2.37) 7.02 (2.12) 0.47 2.28 (0.023) 0.93 (0.13 to 1.73)
Post-treatment 6.77 (2.28) 7.47 (2.15) 0.53 2.52 (0.012) 1.04 (0.23 to 1.84)
CERQ Self-blame (0–20) *
Baseline 5.14 (2.39) 4.47 (2.26)
6 weeks 4.63 (2.01) 4.24 (2.09) 0.12 1.14 (0.256) 0.40 (−0.29 to 1.08)
Post-treatment 4.43 (2.13) 3.74 (1.96) 0.14 0.03 (0.980) 0.01 (−0.68 to 0.70)
CERQ Rumination (0–20) *
Baseline 6.45 (2.33) 5.89 (2.11)
6 weeks 5.80 (2.21) 5.36 (2.06) 0.03 0.30 (0.763) 0.11 (−0.60 to 0.82)
Post-treatment 5.84 (2.48) 4.70 (2.10) 0.47 −1.60 (0.110) −0.59 (−1.32 to 0.13)
CERQ Refocusing (0–20) *
Baseline 4.48 (1.94) 4.26 (1.92)
6 weeks 4.70 (1.99) 5.19 (2.11) 0.52 2.50 (0.013) 0.80 (0.17 to 1.42)
Post-treatment 4.77 (2.13) 5.82 (2.20) 0.99 4.49 (<0.001) 1.47 (0.83 to 2.11)
CERQ Planning (0–20) *
Baseline 5.58 (2.11) 5.41 (2.20)
6 weeks 5.63 (2.17) 6.38 (2) 0.58 2.71 (0.007) 0.98 (0.27 to 1.70)
Post-treatment 5.28 (2.23) 6.40 (2.11) 0.83 3.76 (<0.001) 1.38 (0.65 to 2.11)
CERQ Positive reappraisal
(0–20) *
Baseline 5.12 (2.11) 4.96 (2.42)
6 weeks 4.80 (1.77) 6.07 (2.26) 0.92 4.17 (<0.001) 1.44 (0.76 to 2.11)
Post-treatment 4.67 (2.23) 6.42 (2.28) 1.42 6.27 (<0.001) 2.19 (1.50 to 2.87)
CERQ Perspective (0–20) *
Baseline 5.45 (2.25) 5.45 (2.23)
6 weeks 5.52 (2.08) 6.03 (2.14) 0.17 0.79 (0.431) 0.27 (−0.40 to 0.93)
Post-treatment 5.23 (1.95) 6.46 (2.51) 0.71 3.15 (0.002) 1.12 (0.42 to 1.81)
CERQ Catastrophizing (0–20) *
Baseline 5.34 (2.37) 5.27 (2.17)
6 weeks 4.87 (2.07) 4.09 (1.83) 0.47 −2.04 (0.043) −0.65 (−1.27 to −0.02)
Post-treatment 5.04 (2.21) 3.70 (1.72) 0.85 −3.64 (<0.001) −1.18 (−1.82 to −0.54)
CERQ Blame others (0–20) *
Baseline 3.45 (2.16) 3.42 (2.20)
6 weeks 3.20 (1.65) 2.97 (1.62) 0.14 −1.23 (0.219) −0.34 (−0.88 to 0.20)
Post-treatment 3.20 (1.70) 3.02 (1.72) 0.11 −0.50 (0.620) −0.14 (−0.69 to 0.41)
Note: Mean and SD are not adjusted. When the Benjamini–Hochberg correction was applied to correct for multiple
comparisons, the following effects were not statistically significant: CERQ catastrophizing (p = 0.063). The number
of participants varied across assessment periods due to dropouts (see flow chart). Significant values (p < 0.05) are
shown in bold. * The baseline level of the variable is a significant covariate in the model. B, regression coefficients; CI,
confidence interval; d, Cohen’s d as an effect size measure; ITT, intention-to-treat; NAT-FM; TAU, treatment-as-usual;
TSK, Tampa scale for kinesiophobia; PCS, pain catastrophizing scale; PPCS personal perceived competence scale;
CERQ, cognitive emotion regulation questionnaire.
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3.6. Effects of the Different Activities Included in TAU + NAT-FM Treatment: Intra-Session
Assessments (EMA)
To explore the effect of the different activities included in the TAU + NAT-FM treatment (i.e.,
yoga, Nordic walking, nature photography, and Shinrin Yoku), we analyzed, for each activity, the
change produced in affective valence, arousal, dominance, fatigue, pain, stress, and self-efficacy after
practicing the activity. The results are displayed in Figure 2.
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(EMA). Note: all p values < 0.05 except for fatigue in photography (p = 0.92), and fatigue (p = 0.95) and
pain (p = 0.15) in Nordic walking. NAT-FM, nature activity therapy for fibromyalgia.
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After practicing Nordic walking, the patients reported an improvement in affective valence,
arousal, dominance, stress and self-efficacy (all p values < 0.05), except for pain and fatigue. After
yoga, the patients showed an improvement in all variables analyzed (all p values < 0.05). Photography
was associated with improvements in all variables (all p values < 0.05), except fatigue. And Shinrin
Yoku, like yoga, produced an improvement in all variables analyzed.
3.7. The Role of Kinesiophobia, Pain Catastrophism, Perceived Competence, and Cognitive Emotion Regulation
Strategies as Treatment Mediators
We computed bivariate correlational analyses between pre–posttreatment differences in the
primary and secondary outcomes and baseline to 6-week changes in the process variables within the
TAU + NAT-FM group (Supplementary Table S1) following the model drawn in the Figure 3. The path
analysis results are detailed in Table 6 and illustrated in Figure 2.
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Figure 3. Multiple mediational model with two mediators (generic example). When the relationship
between study arm and outcome is explained by the mediators (Mediator 1 and Mediator 2), it is called
full mediational model. Furthermore, the model is consistent with partial mediation when the study
arm still has a direct effect on outcome after including the mediators.
Two of the 10 tested path models did not show a partial or total mediation effect. Some of the 8
models with significant mediational effects (i.e., Fatigue, HADS-D, PANAS-NA, and RSES) did not
yield significant direct paths between the treatment arm and clinical outcomes, meaning that there was
a total mediation; in the remaining cases, the mediation was partial.
In the mediational model for the FIQR, the two significant mediators were TSK and PPCS (partial
mediation), and the same was observed for HADS-A, HADS-D, and SF-36. In the case of VAS Pain, the
treatment arm predicted the change in TSK and in PPCS at 6-week assessment, which in turn predicted
the change in VAS pain scores at posttreatment (partial mediation). For VAS Fatigue, the treatment arm
predicted the change in TSK, which in turn predicted the posttreatment change in this clinical outcome
(total mediation). The mediati nal model for PANAS-NA resulted in only one mediator (PPCS), which
was also the case for RSES (CERQ-positive reappraisal). No significant mediators were fou d for PSS
and PANAS-PA.
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Table 6. Direct and bootstrap indirect effects in the multiple mediational models of TAU+NAT-FM vs.
TAU (effects of pre- to mid-treatment changes in process variables on pre-to-post changes in primary
and secondary outcomes).
Outcome and Mediators (R2) Direct Effects Indirect Effects
Path Coeff. SE p Path Boot. SE 95% CI
FIQR (0.48)
M1 = TSK (0.17) a1 −5.39 1.21 <0.001 a1 × b1 −4.10 1.29 −7.22 to −2.06a2 7.50 1.46 <0.001
M2 = PPCS (0.21) b1 0.76 0.19 <0.001 a2 × b2 −4.23 1.83 −8.39 to −1.25b2 −0.56 0.19 0.002
c’ −9.76 2.79 <0.001
VAS Pain (0.30)
M1 = TSK (0.17) a1 −5.39 1.19 <0.001 a1 × b1 −0.44 0.19 −0.89 to −0.13a2 7.50 1.46 <0.001
M2 = PPCS (0.21) b1 0.08 0.03 0.008 a2 × b2 −0.38 0.19 −0.82 to −0.07b2 −0.05 0.02 0.010
c’ −1.00 0.39 0.010
VAS Fatigue (0.20)
M1 = TSK (0.17) a1 −5.39 1.18 <0.001 a1 × b1 −0.64 0.22 −1.16 to −0.29b1 0.12 0.04 0.004
c’ −0.76 0.49 0.120
HADS Anxiety (0.41)
M1 = TSK (0.17) a1 −5.39 1.19 <0.001 a1 × b1 −0.56 0.29 −1.28 to −0.11a2 7.50 1.46 <0.001
M2 = PPCS (0.21) b1 0.10 0.05 0.022 a2 × b2 −1.31 0.50 −2.54 to −0.54b2 −0.17 0.05 <0.001
c’ −1.39 0.58 0.017
HADS Depression (0.37)
M1 = TSK (0.17) a1 −5.39 1.21 <0.001 a1 × b1 −0.70 0.29 −1.40 to −0.23a2 5.40 1.45 <0.001
M2 = PPCS (0.21) b1 0.13 0.05 0.008 a2 × b2 −1.17 0.57 −2.47 to −0.28b2 −0.16 0.06 0.011
c’ −1.60 0.83 0.055
SF36 (0.40)
M1 = TSK (0.17) a1 −5.39 1.19 <0.001 a1 × b1 3.06 1.63 0.48 to 7.09a2 7.50 1.46 <0.001
M2 = PPCS (0.21) b1 −0.57 0.27 0.036 a2 × b2 4.47 1.84 1.59 to 8.92b2 0.60 0.20 0.003
c’ 10.57 3.07 0.001
PANAS—(0.12)
M1 = PPCS (0.21) a1 7.50 1.47 <0.001 a1 × b1 −1.43 0.53 −2.60 to −0.49b1 −0.19 0.06 0.003
c’ 0.98 1.06 0.355
RSES (0.06)
M1 = CERQ Positive
Reappraisal (0.17)
a1 1.91 0.41 <0.001 a1 × b1 −0.66 0.34 −1.45 to −0.09b1 −0.35 0.17 0.040
c’ 0.41 0.67 0.539
Note: For clarity, a generic example of a multiple mediational model (with two mediators) is displayed in Figure 2.
CERQ, cognitive emotion regulation questionnaire; HADS, hospital anxiety and depression scale; FIQR, fibromyalgia
impact questionnaire—revised; PANAS, positive affect negative affect scale; PPCS, personal perceived competence
scale; RSES, Rosenberg self-esteem scale; SF-36, 36 items short form survey; TSK, Tampa scale for kinesiophobia;
VAS, visual analogue scale.
4. Discussion
To our knowledge, this is the first study to report the effectiveness of a multicomponent treatment
that includes the combination of PNE, TE, CBT, MT and exposure to nature for the treatment of FM.
J. Clin. Med. 2020, 9, 3348 18 of 24
A recent RCT; the FIBROWALK study [27], has demonstrated the effectiveness of combining these
components, but it did not integrate exposure to nature.
The primary aim of the present study was to analyze the effectiveness of a 12-week multicomponent
treatment based on PNE, TE, NA, CBT, MT, and nature exposure, as an add-on to TAU to improve
a wide range of FM-related outcomes. Data analyses revealed that TAU + NAT-FM (added to TAU)
compared with TAU alone was an effective adjuvant therapy for patients with FM. TAU + NAT-FM
achieved significant results with a large effect size at posttreatment on the primary outcome (i.e.,
functional impairment) and on the following secondary variables: pain, fatigue, anxiety, depression
and physical function; and on the process variables of kinesiophobia, pain catastrophizing thoughts,
personal perceived competence, cognitive emotion regulation subscales (refocusing, planning, positive
reappraisal and catastrophizing). These large effect sizes had already been achieved at 6-weeks of
treatment regarding functional impairment, anxiety, kinesiophobia, personal perceived competence,
and positive reappraisal. In addition, significant results with moderate effect size were obtained at
six-weeks for pain, fatigue, physical function, personal perceived competence, refocusing (CERQ),
and planning (CERQ). Our results indicate that these beneficial outcomes are achieved as therapy
progresses, but at six-weeks there is already a significant (but not yet complete) improvement in the
main outcomes analyzed in these FM patients. Further studies should be conducted to investigate
how extending the therapy to include more sessions could have an impact on (1) the therapeutic effect
achieved and (2) maintenance of the effects achieved post-therapy.
In accordance with the findings reported in the previous literature [16,17,27] the TAU + NAT-FM
intervention appears to be an effective multicomponent intervention for improving FM symptoms,
at least in terms of functional impairment, pain, fatigue, anxiety, depression, physical function, and
kinesiophobia. More recently [24], education, psychological support and exercise therapy have been
shown to be the most effective combined strategies. To date, studies have reported effect sizes of small
to moderate magnitude. Although there are yet no curative treatments for FM, when using the TAU +
NAT-FM intervention, the active group not only showed that this intervention had a large effect on the
main outcomes, but 66.7% achieved a decrease in their FIQR score by at least 20% when compared
with baseline assessment, 1.3% achieved a decrease of at least 70%, 8.1% achieved a decrease of at
least 60%, along with an NNT of 3. The responder group had higher BMI, age, years of illness and
perspective, and lower baseline scores on anxiety, depression, and pain catastrophizing thoughts. The
non-responder group, as shown in the TAU + NAT-FM and FIBROWALK intervention, had, at least,
higher scores on depression according to previous literature [27,69,70].
The FIBROWALK study [27] also found significant differences with large effect size at posttreatment
on the primary outcome: functional impairment, and on pain, physical function and kinesiophobia
(secondary outcomes), along with significant differences of moderate effect size at posttreatment for
fatigue, anxiety and depression (secondary outcomes. Further, 51.85% reached the criterion of ≥20%
FIQR reduction, a total of 7 patients (5.2%) showed a reduction in their FIQR score by more than 70%,
with an NNT of 2. More studies are needed to confirm the other significant differences that have been
reported with the TAU + NAT-FM intervention.
The improvements generated by the TAU + NAT-FM intervention on the effect sizes of certain
outcomes could be due not only to the effect of combining these interventions but also to the exposure
to nature. Our preliminarily assessment of the effect of the various activities included in the TAU +
NAT-FM intervention has revealed that these activities could be useful for improving certain emotional
and cognitive targets. Yoga and Shinrin Yoku appear to be promising for the improvement of affective
valence, arousal, dominance, fatigue, pain, stress and self-efficacy; nature photography appears to
improve all variables except for fatigue; whilst Nordic walking could improve all variables apart from
fatigue and pain. The results of EMA intrasession provided preliminary evidence of the positive
effect of the psychical activities practiced in nature. Consistent with previous research, interventions
based on physical activity in nature yielded a positive effect on emotional, cognitive and behavioral
functioning [29–34,37].
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Future studies on this type of multicomponent intervention should identify the elements that
make the most significant contribution to the effects of the TAU + NAT-FM, and should also focus on
long-term clinical outcomes compared with TAU, whilst providing more detailed information about
the potential role played by the nature-based activities explored in this study.
Mediation analyses revealed that pre-post changes in kinesiophobia and personal perceived
competence partially mediated the relationships between study condition and functional impact,
anxiety, depression and physical function. A total mediation effect was found for kinesiophobia on
the relationship between study condition and fatigue, for perceived competence in the link between
study condition and negative affect, and for positive reappraisal (CERQ) in the study condition and
self-esteem (RSES) relationship. Our results suggest that these mediators could explain a large part of
the improvements, and we should focus our attention on these mediators for improving the TAU +
NAT-FM therapeutic process. However, in this regard, it would be of interest for future research to
evaluate whether other mediators could be involved in the main components of TAU + NAT-FM.
Limitations and Strengths of This Study
Due to the fact that this clinical research was conducted by the main researcher (M.S.) in the
context of real-life clinical practice in a specialized unit of a tertiary referral hospital, and that it is
currently not possible to change these conditions, the main limitations of this work are the same as
those described in a previous study [27]. To sum up, these limitations were: (a) the impossibility of
applying strict selection criteria, (b) no follow up of the sample beyond post treatment, (c) absence of
blinding in the group assignment, (d) the intervention was conducted by only one therapist, although
the therapist is also a physiotherapist, psychologist and mountain sports technician, which provides the
knowledge required to apply this multicomponent therapy; (e) the high number of patients per group
(20), and (f) the high chronic disease duration with high baseline values of the main core symptoms
of FM of the patients recruited. Consideration of the relevance of this approach as a complementary
model of health intervention and its evaluation in primary care patients could help to resolve the
limitations described above.
With regard to the effect of the various activities included in TAU + NAT-FM, certain limitations
are worth noting. First, not every activity was performed with the same frequency, with yoga being
the one that was most often practiced and registered. The format of the sessions and the subsequent
assessment of the effect of the activity (i.e., one activity began immediately after the other had finished)
means that it is not possible to reliably compare the activities, as those which were performed second
would quite possibly be affected by the previous activity. For these reasons, the results presented must
be regarded as preliminary and, in order to assess the differential effect of each activity, further studies
could try to adapt this methodology, assessing only the effect of the first activity in each session, and
ensuring that a similar number of records is obtained for each activity.
Due to the lack of follow-up, the mediation analyses could only be performed with the changes
observed in the process variables between the baseline evaluation and the six-week assessment.
These results should be replicated considering, if possible, how the pre-post treatment changes in
these variables could mediate the long-term changes in the main variables (i.e., pain, fatigue, and
functional impact, among others). Moreover, some other relevant process variables could be included
in further studies, such as, for instance, psychological inflexibility or the mindfulness facet “acting
with awareness”, which have proved to be significant mediators of long-term changes produced by a
mindfulness-based intervention for patients with FM [15].
To our knowledge, this is also the first study to demonstrate the effectiveness of a multicomponent
treatment that specifically integrates nature exposure in patients with FM. There are a number of
studies supporting the effectiveness of each or a combination of two or more components of the
intervention that constitute this multicomponent approach [19–26,29–34,36]. Although integrating
the different therapeutic interventions was a complex process, the TAU + NAT-FM approach was
designed with a clear and replicable methodology [27,28,36] and it is based on an empirically validated
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framework. The relatively low dropout rate was made possible due to the use of certain therapeutic
adherence strategies whereby phone and mail contacts were established with FM patients [27].
5. Conclusions
In conclusion, the TAU + NAT-FM treatment is presented as the first intervention that integrates
PNE, TE, CBT, MT, and exposure to the natural environment. It is based on recognized scientific
evidence reported in various studies in the three central components of treatment (NAT: nature activity
therapy). The results of this study suggest that the TAU + NAT-FM intervention (added to TAU)
could emerge as an add-on therapy conceived as a new generation of therapeutic intervention that
not only improves the core symptoms of this prevalent and costly disease in comparison with usual
treatments, but also one that is of benefit both socially, due to the high use of public resources, and
economically, due to the high consumption of health resources and job losses resulting from this illness.
It also provides novel and useful information to promote a future paradigm shift in the management
of FM, chronic pain in general, and various other health problems by combining different approaches
in natural contexts.
This study highlights the need to consider the relevance of this approach as a complementary
model of health intervention that could be applied and evaluated in primary care patients.
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